Equity Details
Price & Market Data
Price: $3.68
Daily Change: -$0.11 / 2.99%
Daily Range: $3.26 - $3.95
Market Cap: $247,772,224
Daily Volume: 147,328
Performance Metrics
1 Week: 6.94%
1 Month: 2.12%
3 Months: 20.88%
6 Months: 121.3%
1 Year: 137.6%
YTD: 105.9%
About Adagene Inc. (ADAG)
Understand Adagene Inc. (ADAG)'s market. Price: 3.68, daily change: -$0.11 / 2.99%. Market cap: 247,772,224. Performance 1-month, 6-month, 52-week.
Company Details
Employees: 128
Sector: Health technology
Industry: Pharmaceuticals: major
Country: China
Details
Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People's Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer. The company also develops ADG116, a fully human anti-CTLA-4 antibody generated using NEObody technology, which is in phase 1b/2 clinical trials to treat advanced/metastatic solid tumors; ADG206, which is in phase 1 clinical development to treat advanced metastatic solid tumors; ADG104, anti-PD-L1 monoclonal antibody which is in phase 2 clinical development; and ADG125, a novel anti-CSF-1R mAb which is in Phase 2 clinical development. In addition, it is developing ADG138, a HER2xCD3 POWERbody which is in pre clinical trial to treat low expressing tumors, as well as resistant/refractory tumors; ADG152, a CD20xCD3 POWERbody which is in preclincal trial to treat off-tumor toxicities; ADG153, a masked anti-CD47 IgG1 SAFEbody, wihx is in preclinical trial for the treatment of hematologic and solid tumor; and CD28 T-cell engagers, an anti-CD28 bispecific POWERbody TCEs to treat solid tumors. Adagene Inc. was incorporated in 2011 and is headquartered in Suzhou, China.
